A Phase <scp>II</scp> Trial of Lutikizumab, an Anti–Interleukin‐1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis
Roy Fleischmann(Metroplex Clinical Research Center), Marc C. Levesque(AbbVie (United States)), Francisco J. Blanco(Complexo Hospitalario Universitario A Coruña), Lanju Zhang(AbbVie (United States)), Thomas J. Schnitzer, Johanne Martel‐Pelletier(Centre Hospitalier de l’Université de Montréal), Gurjit S. Kaeley(University of Florida), Matthew P. Kosloski(AbbVie (United States)), Françis Berenbaum(Inserm), Li Wang(AbbVie (United States)), Wei Liu(AbbVie (United States)), Philip G. Conaghan(University of Leeds), Su Chen(The Affiliated Yongchuan Hospital of Chongqing Medical University), Sheng Feng(AbbVie (United States)), Charles G. Peterfy(Boca Raton Regional Hospital), Ole Vaeterlein(BioClinica (United States)), G Levy(AbbVie (United States)), Jean‐Pierre Pelletier(Université de Montréal), Henning Bliddal(Frederiksberg Hospital)
Cited by 209
Related Papers
Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
|New England Journal of Medicine|2000|4k
A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
|New England Journal of Medicine|2000|1.8k
EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis
|Annals of the Rheumatic Diseases|2013|1.4k
Clopidogrel with or without Omeprazole in Coronary Artery Disease
|New England Journal of Medicine|2010|1.2k